Navigation Links
Digirad Corporation Comments on Fourth Quarter Progress
Date:1/14/2009

POWAY, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Digirad Corporation (Nasdaq: DRAD), a leading provider of medical diagnostic imaging systems and personnel and equipment leasing services to physicians' offices, hospitals and imaging centers, today announced that results for the 2008 fourth quarter will show positive progress toward both organizational and financial turnaround goals laid out by CEO Todd Clyde following his promotion in to that role in October 2008. Indications of that progress include:

-- The Product Division was profitable for the year and for the quarter on the strength of double-digit unit and revenue growth in the fourth quarter over fourth quarter 2007. The company had established the goal of profitability for the year in the division at the beginning of 2008.

-- The Centers of Influence (COI) model, which pairs leading academic centers with a network of community practitioners to drive growth and utilization, continues to work as the more established COI locations also showed growth in the quarter over the prior year.

-- Negotiations for the sale or closure of underperforming hub locations began during the fourth quarter and are well underway. Those transactions should begin to close during the next 60 days and are expected to be complete within six months. The locations generated nearly $7 million of revenue during 2008.

-- The company's operations generated more than $2 million in cash during the 2008 fourth quarter, bolstering its cash, cash equivalents and securities to more than $28 million, or approximately $1.50/share at December 31.

Digirad CEO Todd Clyde said, "The entire organization is focused on achieving positive cash flow and profitability in the near term while driving technology progress and improving services utilization to grow market share over the long run. I have been pleased with the employee response to our initiatives in the fourth quarter of 2008 and look forward to sharing our progress in greater detail when we report our full annual results in February."

As previously announced, Clyde will be presenting at J.P. Morgan's 27th Annual Healthcare Conference being held January 12-15, at the Westin St. Francis Hotel, San Francisco. His presentation is scheduled to begin at 11:30 a.m. PT tomorrow, Thursday, January 15. The presentation will include a discussion of Digirad's business, strategic focus and outlook. The presentation will also be webcast live on the events and presentation page of the investors section of Digirad's web site at www.digirad.com. An archive of the presentation will be accessible at this site for 90 days.

About Digirad Corporation

Digirad provides medical diagnostic imaging systems and personnel and equipment leasing services to physicians' offices, hospitals and imaging centers for cardiac, vascular, and general imaging applications. Digirad's Cardius XPO line of nuclear imaging cameras use patented solid-state technology and unique multi (single, dual, triple) head design for superior performance and advanced features for sharper digital images, faster processing, compact size, lighter weight for portability, ability to handle patients up to 500 pounds, and improved patient comfort compared to standard nuclear cameras. Digirad's 2020tc general-purpose nuclear imager has a small footprint and may also be configured for fixed or mobile use to supplement primary imaging. Digirad's installed base of equipment exceeds 600 systems; in addition, a mobile fleet of more than 145 nuclear and ultrasound imaging systems is being used in 21 states, primarily in the eastern, midwestern and southwestern United States. For more information, please visit www.digirad.com. Digirad(R), Digirad Imaging Solutions(R), and Cardius(R) are registered trademarks of Digirad Corporation.

Forward-Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. These include statements regarding the efficacy of Digirad's centers of influence model, the status of the negotiation of the sale or closure of underperforming hub locations, and the ability to achieve positive cash flow and profitability, drive technology progress and improve services utilization to grow market share. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made, including the risks associated with changes in business conditions, technology, customers' business conditions, work force, suppliers, business prospects, economic outlook, operational policy or structure, acceptance and use of Digirad's camera systems and services, reliability, recalls, and other risks detailed in Digirad's filings with the U.S. Securities and Exchange Commission, including Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward looking statements, which speak only as of the date hereof. All forward looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward looking statements contained herein.

     Investor Contact:            Company Contact:
     Matt Clawson                 Todd Clyde
     Allen & Caron                Chief Executive Officer
     949-474-4300                 858-726-1600

'/>"/>
SOURCE Digirad Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Digirad Corporation to Release Third Quarter, Nine-Month Financial Results on October 25, 2007
2. Digirad Corporation Named to Deloitte Technology Fast 50
3. Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results
4. Digirad Corporation and The Methodist Hospital in Houston Sign Letter of Agreement
5. Digirad Corporation Board of Directors Appoints R. King Nelson Chairman
6. Digirad to Introduce New Clinical Standard for Cardiac SPECT
7. Digirad Corporation to Release Fourth Quarter, Year-End Financial Results on February 7, 2008
8. Digirad Corporation Appoints John W. Sayward to Its Board of Directors
9. Digirad Corporation to Release First Quarter Financial Results on April 24, 2008
10. Digirad Corporation Reports Financial Results for First-Quarter 2008
11. Digirad Corporation and University of Chicago Medical Center Sign Letter of Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is ... in Building 2. The clinic is the group’s second in New Braunfels and 22nd ... company’s second New Braunfels location brings things full circle for the group, “It’s crazy ...
(Date:3/23/2017)... ... ... 82% of adults are unaware of the dangers that infectious bacteria play in mouth disease, ... times a day that dentists recommend. The ramifications of improper oral upkeep go far beyond ... missing 164 million hours of work each year due to dental issues. That is why ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... Oriented Disease Management Accreditation from the NCQA. The accreditation covers StayWell’s asthma, coronary ... , Accredited status is granted to organizations that have excellent programs for the ...
(Date:3/23/2017)... Fort Collins, CO (PRWEB) , ... March 23, ... ... services firm serving the families and businesses of the greater Fort Collins area, ... charity campaign in their ongoing community involvement program. Donations to this worthy cause ...
(Date:3/23/2017)... ... ... conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... 43rd President of the United States of America: George W. Bush , ... the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... March 23, 2017 As a result ... with the prevalence of allergic diseases, cutting edge ... currently revolutionising the ways in which pharmaceutical and ... 2017 promises to be both a high quality ... allergy interest groups, immunologists, research scholars and doctors. ...
(Date:3/23/2017)... Summary Global ... guide Primary Hyperoxaluria - Pipeline Review, H1 2017, ... Urinary System And Sex Hormones) pipeline landscape. ... recurrent kidney and bladder stones. It results from ... include blood in the urine, pain when urinating, ...
(Date:3/23/2017)... and VANCOUVER, British Columbia , ... SPHS ) (the "Company" or "Sophiris"), a clinical ... of urological diseases, today announced that data from its ... drug as a focal treatment for localized prostate cancer, ... 2017 at the 32 nd Annual European Association ...
Breaking Medicine Technology: